0001562180-23-005323.txt : 20230620
0001562180-23-005323.hdr.sgml : 20230620
20230620110254
ACCESSION NUMBER: 0001562180-23-005323
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230616
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mosca Alison
CENTRAL INDEX KEY: 0001835537
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39834
FILM NUMBER: 231023921
MAIL ADDRESS:
STREET 1: 26 PATRIOT PLACE, SUITE 301
CITY: FOXBORO
STATE: MA
ZIP: 02035
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clene Inc.
CENTRAL INDEX KEY: 0001822791
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 852828339
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
BUSINESS PHONE: 801-676-9695
MAIL ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
FORMER COMPANY:
FORMER CONFORMED NAME: Chelsea Worldwide Inc.
DATE OF NAME CHANGE: 20200827
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0407
4
2023-06-16
false
0001822791
Clene Inc.
CLNN
0001835537
Mosca Alison
6550 SOUTH MILLROCK DRIVE
SUITE G50
SALT LAKE CITY
UT
84121
true
false
false
false
false
Common Stock
2023-06-16
4
P
false
2394375.00
0.80
A
3238375.00
I
By LLC
Common Stock
39476.00
D
Common Stock
3006670.00
I
By LP
Common Stock
1459945.00
I
By trust
Warrants (Right to buy)
1.50
2023-06-16
4
A
false
2394375.00
A
2023-06-16
Common Stock
2394375.00
2394375.00
D
Warrants (Right to buy)
1.10
2023-06-16
4
A
false
2394375.00
A
2023-06-16
Common Stock
2394375.00
2394375.00
D
The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. Please note that Kensington Clene 2021, LLC had been incorrectly referred to in prior form 4s for Ms. Mosca as Kensington Clene, LLC; there is no such legal entity, only Kensington Clene 2021, LLC.
The securities are owned by the Kensington Investments, L.P. Ms. Mosca is the chief executive officer of Kensington Investments, L.P. The shares owned by the Kensington Investments, L.P. may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Investments, L.P. , for which she does not have a pecuniary or profits interest.
The securities are owned by the Robert C. Gay 1998 Family Trust. Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust. The shares owned by the Robert C. Gay 1998 Family Trust may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust.
The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
Kensington Clene 2021, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 2,394,375 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration approval of a New Drug Application from Clene Inc. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.
Kensington Clene 2021, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 2,394,375 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.
/s/ Jerry Miraglia POA
2023-06-20